Bicara Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bicara Therapeutics (BCAX).

Price Target Range — 9 Quarters

Analyst Consensus — 14 Analysts

1S.Buy

11Buy

2Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$33Upside to Avg. PT+80.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$39
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$35
Aug 12, 2026	Goldman Sachs	Richard Law	PT Raise	Neutral	$18→$20
Aug 12, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$30→$33
Aug 12, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$37→$39
Aug 12, 2026	Mizuho	Joseph Catanzaro	PT Raise	Neutral	$18→$20
Aug 12, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$16→$23
Aug 12, 2026	BTIG	Jeet Mukherjee	PT Raise	Buy	$28→$39
May 12, 2026	Goldman Sachs	Richard Law	PT Raise	Neutral	$16→$18
May 12, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$36→$37
May 11, 2026	Guggenheim	Brad Canino	Initiate	Buy	$42
Mar 31, 2026	Goldman Sachs	Richard Law	PT Raise	Neutral	$14→$16
Mar 31, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$30
Mar 31, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$11→$16
Mar 31, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$31
Mar 31, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$40→$42
Mar 25, 2026	B of A Securities	Tazeen Ahmad	Initiate	Buy	$35
Jan 29, 2026	Citizens	Reni J. Benjamin	Initiate	Market Outperform	$31
Jan 13, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$30
Jan 8, 2026	BTIG	Jeet Mukherjee	Initiate	Buy	$28

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target

BTIG analyst Jeet Mukherjee reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Buy and maintains $39 price target.

Benzinga Newsdesk

PRO
BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35

BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Outperform rating and announces Price Target of $35.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33

Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and raises the price target from $30 to $33.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39

Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $37 to $39.

Benzinga Newsdesk

PRO
Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

Mizuho analyst Joseph Catanzaro maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.

Benzinga Newsdesk

Bicara Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Bicara Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target

PRO
BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35

PRO
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

PRO
Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33

PRO
Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39

PRO
Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

People Also Watch

People Also Watch

Bicara Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Bicara Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target

PROBMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35

PROGoldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

PROWedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33

PROMorgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39

PROMizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

People Also Watch

People Also Watch

PRO
BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target

PRO
BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35

PRO
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

PRO
Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33

PRO
Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39

PRO
Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20